

Medinice S.A.
Ul. Stefana Hankiewicza 2
02-103 Warsaw

CURRENT REPORT NO. 16/2026
DATED 21 APRIL 2026

Title: Commencement of due diligence concerning the CoolCryo medical device

Legal basis: Article 17(1) of MAR – inside information

The Management Board of Medinice S.A. with its registered office in Warsaw ("Issuer") informs that on 21 April 2026 due diligence concerning the CoolCryo medical device commenced. The purpose of the due diligence is for the potential acquirer to obtain knowledge about the legal and factual status of CoolCryo, and then to prepare an purchase offer of CoolCryo. The potential acquirer for whose benefit the due diligence is being conducted is a large industry entity operating on an international scale.

The Issuer's Management Board reminds that this is the second and independent process of this type in relation to CoolCryo. The first one begun directly after the signing of the letter of intent, about which the Company informed on 23 January this year in ESPI report No. 4/2026.

CoolCryo is a medical device intended for the treatment of cardiac arrhythmias through the performance of surgical cryoablation. CoolCryo has been approved for marketing in the United States market, of which the Issuer informed in current ESPI report No. 5/2026 dated 13 February 2026.

The Issuer publishes this information due to the fact that the potential disposal of CoolCryo, which may result from the due diligence, may have a very significant positive impact on the financial situation and results of the Issuer.